INSULET CORP（PODD）の決算・業績分析
INSULET CORPの2025年有価証券報告書をAI分析。売上高$2.7B(+30.7%)。営業利益$474M。Health Care。
目次
INSULET CORPの2025年度 業績サマリー
INSULET CORP（証券コード: PODD）の2025年度決算・業績分析。売上高は$2.7B（前年比+30.7%）。営業利益は$474M（前年比+53.4%）。純利益は$247M（前年比-40.9%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
INSULET CORPの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue grew 18.8% YoY to $1.3B (XBRL), but operating income fell 70.2% YoY to $38M (XBRL).
- Net income dropped 72.6% YoY to $5M (XBRL), despite a 24.7% CAGR in revenue over five years (XBRL).
- CapEx of $123M (XBRL) led to negative free cash flow of $4M (XBRL), with R&D spending at $180M (XBRL).
INSULET CORPの売上高変化の要因
- •Revenue grew to $1.3B (XBRL) in FY2024, up 18.8% YoY and reflecting a 24.7% CAGR over five years (XBRL). The Omnipod product line drives nearly all revenue (10-K), with additional income from Amgen's Neulasta Onpro kit (10-K). Historical time series show revenue increasing from $564M in FY2020 to $1.7B in FY2025 (XBRL). However, operating income fell to $38M (XBRL) in FY2024, down 70.2% YoY, despite a 51.7% CAGR in operating income over five years (XBRL).
INSULET CORPの営業利益変化の要因
- •Gross margin remained strong at 61.7% (XBRL), but operating margin fell to 2.9% (XBRL), down 70.2% YoY. Net margin dropped to 0.3% (XBRL), reflecting a 72.6% YoY decline in net income to $5M (XBRL). EBITDA of $101M (XBRL) represented 7.7% of revenue (XBRL). Historical data shows net income fluctuated between $3M in FY2020 and $206M in FY2025 (XBRL), with a 128.7% CAGR over five years (XBRL).
INSULET CORPの事業リスクと対応
Reliance on Omnipod product for nearly all revenue, with risks from competition, quality issues, or reimbursement changes (10-K).
Failure to maintain acceptance among physicians, payors, and users (10-K).
Manufacturing problems, capacity constraints, or quality issues (10-K).
Adverse regulatory or legal actions affecting products (10-K).
Reimbursement rate reductions or coverage policy changes by payors (10-K).
Competitive threats from patch pumps or breakthrough diabetes treatments (10-K).
INSULET CORPの事業内容
Insulet Corp (PODD) develops, manufactures, and sells proprietary continuous insulin delivery systems for insulin-dependent diabetes (10-K). Its primary products include the Omnipod 5 Automated Insulin Delivery System, Omnipod DASH Insulin Management System, and Classic Omnipod (10-K). Additional revenue comes from producing pods for Amgen's Neulasta Onpro kit (10-K). Key customers are individuals with type 1 diabetes and insulin-intensive type 2 diabetes (10-K). The company's competitive advantage lies in its proprietary Omnipod platform (10-K), though no specific competitors are mentioned in the 10-K.
INSULET CORPのAI業績分析レポート（2024年度）
Annual Report Analysis: Insulet Corp (PODD) FY2024
Highlights
Business Overview
Insulet Corp (PODD) develops, manufactures, and sells proprietary continuous insulin delivery systems for insulin-dependent diabetes (10-K). Its primary products include the Omnipod 5 Automated Insulin Delivery System, Omnipod DASH Insulin Management System, and Classic Omnipod (10-K). Additional revenue comes from producing pods for Amgen's Neulasta Onpro kit (10-K). Key customers are individuals with type 1 diabetes and insulin-intensive type 2 diabetes (10-K). The company's competitive advantage lies in its proprietary Omnipod platform (10-K), though no specific competitors are mentioned in the 10-K.
Revenue Analysis
Revenue grew to $1.3B (XBRL) in FY2024, up 18.8% YoY and reflecting a 24.7% CAGR over five years (XBRL). The Omnipod product line drives nearly all revenue (10-K), with additional income from Amgen's Neulasta Onpro kit (10-K). Historical time series show revenue increasing from $564M in FY2020 to $1.7B in FY2025 (XBRL). However, operating income fell to $38M (XBRL) in FY2024, down 70.2% YoY, despite a 51.7% CAGR in operating income over five years (XBRL).
Profitability Analysis
Gross margin remained strong at 61.7% (XBRL), but operating margin fell to 2.9% (XBRL), down 70.2% YoY. Net margin dropped to 0.3% (XBRL), reflecting a 72.6% YoY decline in net income to $5M (XBRL). EBITDA of $101M (XBRL) represented 7.7% of revenue (XBRL). Historical data shows net income fluctuated between $3M in FY2020 and $206M in FY2025 (XBRL), with a 128.7% CAGR over five years (XBRL).
Balance Sheet Analysis
Total assets grew to $2.6B (XBRL) in FY2024, up from $1.1B in FY2020 (XBRL). Equity ratio declined to 21.5% (XBRL), with debt-to-equity rising to 3.34x (XBRL). Current ratio remained robust at 3.51x (XBRL). Total equity decreased from $158M in FY2020 to $556M in FY2024 (XBRL), though it fell further to $476M in FY2025 (XBRL). ROE and ROA were 0.8% and 0.2% (XBRL), respectively.
Cash Flow Analysis
Operating cash flow increased to $119M (XBRL) in FY2024, but free cash flow turned negative at $4M (XBRL) due to $123M in CapEx (XBRL). Investing cash flow was -$191M (XBRL), and financing cash flow was -$40M (XBRL). CapEx intensity was 9.4% (XBRL), with CapEx/D&A ratio at 1.94x (XBRL). R&D spending reached $180M (XBRL).
Working Capital Analysis
N/A
Risks
Outlook
N/A
Health Careの企業一覧
INSULET CORPと同じ「Health Care」セクターの企業